Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats

1996 ◽  
Vol 122 (7) ◽  
pp. 421-426 ◽  
Author(s):  
S. Kurth ◽  
D. Bulian ◽  
B. Kreft ◽  
Th. Riemenschneider
Keyword(s):  
Mitomycin C ◽  
Anticancer Drugs ◽  
Liver Tumor ◽  
Single Agent ◽  
Experimental Liver

New method of photosensitizer accumulation for photodynamic therapy in an experimental liver tumor

1989 ◽  
Vol 9 (3) ◽  
pp. 254-263 ◽  
Author(s):  
Yoshiro Nishiwaki ◽  
Satoshi Nakamura ◽  
Shukichi Sakaguchi
Keyword(s):  
Photodynamic Therapy ◽  
Liver Tumor ◽  
New Method ◽  
Experimental Liver

Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14083-14083 ◽  
Author(s):  
D. Shin ◽  
S. Lee ◽  
S. Park ◽  
S. Bang ◽  
E. Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Single Agent ◽  
Objective Response ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Previously Treated ◽  
Line Chemotherapy

14083 Background: S-1, a fourth generation oral fluoropyrimidine that mimics infusional 5-fluorouracil, has demonstrated activity against advanced gastric cancer. Based on a single agent activity and in vitro synergy between mitomycin C (MMC) and 5-fluorouracil, we conducted a phase II study to assess the efficacy and tolerability of the combination of S-1 and MMC as second-line chemotherapy for previously treated, advanced gastric cancer. Methods: Patients with measurable gastric cancer, progressive after at least one prior chemotherapy for metastatic disease, were treated with MMC 7 mg/m2 on day 1 and S-1 40 mg/m2 twice daily as an intermittent regimen of 4 weeks of treatment followed by a 2-week rest. Treatment was repeated every 6 weeks, for up to 4 cycles. Objective response rate was the primary endpoint and was evaluated every 2 cycles of chemotherapy. With a single-stage phase II design, at least 25 patients were required. Results: Of the 26 patients registered, 24 patients were evaluable for response and 26 for safety. Eighteen patients (69%) were previously treated with 5-fluorouracil-based chemotherapy, and 10 (39%) were treated with taxanes. The patients’ median age was 55 years (range, 38–73) and 7 (27%) had an ECOG performance status of 2. A total of 64 chemotherapy cycles were delivered (median, 2; range, 1–4). In an intent-to-treat analysis, 6 patients (23%) achieved a partial response, which maintained for 3.5 months. The median progression-free and overall survivals were 4.4 months (95% CI, 1.7–7.2) and 5.4 months (95% CI, 3.4–7.4), respectively. Major toxic effects included stomatitis, diarrhea and fatigue, but were generally mild and manageable. No patient developed hemolytic reaction. Conclusions: Second-line chemotherapy with MMC and S-1 is an effective regimen for advanced gastric cancer with an acceptable toxicity profile and a convenient administration schedule. No significant financial relationships to disclose.

Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor

2006 ◽  
Vol 46 (3) ◽  
pp. 211-217 ◽  
Author(s):  
Yang Xi-xiao ◽  
Chen Jan-hai ◽  
Liu Shi-ting ◽  
Guo Dan ◽  
Zeng Xv-xin
Keyword(s):  
Mitomycin C ◽  
Liver Tumor

scholarly journals Preparation and characterization of ferromagnetic mitomycin C microcapsules as a means of magnetic control of anticancer drugs.

1979 ◽  
Vol 55 (9) ◽  
pp. 470-475 ◽  
Author(s):  
Tetsuro KATO ◽  
Ryosuke NEMOTO ◽  
Hisashi MORI ◽  
Katsuo UNNO ◽  
Akio GOTO ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Anticancer Drugs ◽  
Magnetic Control

Combined Therapy of Mitomycin C and Chinese Medical Herbs on Experimental Liver Cancer

1993 ◽  
Vol 21 (01) ◽  
pp. 51-58 ◽  
Author(s):  
Dou-Mong Hau ◽  
Tai-Hei Chen ◽  
Jau-Forng Cheng ◽  
Jyu-Sheng You
Keyword(s):  
Mortality Rate ◽  
Liver Cancer ◽  
Mitomycin C ◽  
Combined Therapy ◽  
Tumor Control ◽  
Sarcoma 180 ◽  
Male Mice ◽  
Mean Survival Time ◽  
The Mean ◽  
Experimental Liver

In this research, ICR male mice were chosen for intrahepatic implantation of sarcoma 180 tumor cells (1 × 107). The mice were randomly divided into various groups 24 hours after implantation. One of the groups was the tumor control, the others were singly or combinedly treated with mitomycin C (MMC) and Shih Chuan-Ta-Pu-Tang (SCTPT) or Shi-Hung-One (SHO). The results revealed that the mortality rate (MR60) in the tumor control was 100% and the mean survival time (MST60) was 21.11 ± 10.69 days. The best therapeutic effect appeared in the group treated with the combination of MMC and SHO, its MR6o was 55.0% and MST 60 was 47.0 ± 13.4 days.

Mitomycin C and Vinorelbine in Pretreated Breast Cancer

1997 ◽  
Vol 83 (5) ◽  
pp. 834-836 ◽  
Author(s):  
Marco Colleoni ◽  
Paolo Manente ◽  
Joan Stocker ◽  
Herbert Amor ◽  
Stefano Lamon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Side Effects ◽  
Confidence Interval ◽  
Mitomycin C ◽  
Single Agent ◽  
Vinca Alkaloid ◽  
Metastatic Breast ◽  
Moderate Activity ◽  
Grade Iii

Aims and background Vinorelbine, a new semi-synthetic vinca alkaloid, has demonstrated high activity as a single agent in pretreated metastatic breast cancer. Patients and methods To evaluate the activity of the combination vinorelbine-mitomycin C and to reduce the incidence of side effects, in particular myelotoxicity, patients with metastatic breast cancer pretreated with 1 or more chemotherapy regimens for metastatic disease were treated according to the following schedule: mitomycin C, 10 mg/m2 day 1, and vinorelbine, 25 mg/m2, days 1, 8 and 15, every 28 days. Results Twenty-seven patients were enrolled and were evaluable for activity and side effects. A total of 157 cycles were delivered (median 5 cycles per patient). There were 10 partial remissions (37%; 95% confidence interval 20-59%), 5 instances of stable disease and 12 of disease progression. Grade III-IV toxicity was mostly hematological and included thrombocytopenia (4%) and neutropenia (42%). Conclusion Our results indicate that the combination of mitomycin C and vinorelbine has moderate activity in pretreated breast cancer.

scholarly journals Transarterial Delivery of a Biodegradable Single-Agent Theranostic Nanoprobe for Liver Tumor Imaging and Combinatorial Phototherapy

2019 ◽  
Vol 30 (9) ◽  
pp. 1480-1486.e2 ◽  
Author(s):  
Olena R. Taratula ◽  
Oleh Taratula ◽  
Xiangjun Han ◽  
Younes Jahangiri ◽  
Yuki Tomozawa ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Tumor Imaging ◽  
Single Agent

Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol®), mitomycin C and doxorubicin

1998 ◽  
Vol 8 (23) ◽  
pp. 3347-3352 ◽  
Author(s):  
Gene M. Dubowchik ◽  
Kathleen Mosure ◽  
Jay O. Knipe ◽  
Raymond A. Firestone
Keyword(s):  
Mitomycin C ◽  
Anticancer Drugs ◽  
Cathepsin B
Sign in / Sign up

Export Citation Format

Share Document